US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption on July 07, 2026 Biosecure Act China Clinical Trials concerns Data Security Evaluation House Select Committee Industry lawmakers Merck AbbVie Eli Lilly Pfizer Myers Squibb China Military Hospitals restrictions trials U.S. Xinjiang +